<DOC>
	<DOC>NCT00210431</DOC>
	<brief_summary>The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.</brief_summary>
	<brief_title>Post Marketing Surveillance Study of Dysport</brief_title>
	<detailed_description />
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Hemifacial Spasm</mesh_term>
	<mesh_term>Equinus Deformity</mesh_term>
	<mesh_term>Clubfoot</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<criteria>adult or child over the age of 2 years scheduled to receive Dysport as per their normal treatment practice, and in conformance with their country's Summary of Product Characteristics history of hypersensitivity to Dysport or drugs with a similar chemical structure treatment with any other investigational drug within the last 30 days before survey entry</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>